Status:
ACTIVE_NOT_RECRUITING
Studying the Health of Asians to Advance Knowledge, Treatments, and Interventions for Depression
Lead Sponsor:
University of Texas Southwestern Medical Center
Conditions:
Depression
Treatment Resistant Depression
Eligibility:
All Genders
10+ years
Brief Summary
SHAKTI (from the Sanskrit word for "power") is a 5-year natural history, longitudinal, prospective study of a cohort of 6,000 participants that will help uncover the socio-demographic, lifestyle, clin...
Detailed Description
SHAKTI is a non-randomized, natural history, non-treatment, longitudinal cohort study. Participants who are receiving standard of care treatment for depression and other comorbidities from their treat...
Eligibility Criteria
Inclusion
- Adult or youth aged 10 years or older
- Self-identify fully or partially as being of Asian or Pacific Islander descent such as: East Asian, South Asian, Southeast Asian, Southwest Asian, Central Asian, Oceanian, Pacific Islander, Polynesian, Micronesian, Melanesian
- Have the ability to speak, read, and understand English. The parent(s) or legal guardians of minors must also speak, read and understand English.
- Have the ability to complete clinical evaluations, neuropsychological testing, and self-report measures.
- Meet criteria for one of these three groups:
- Have a lifetime or a current diagnosis of a mood disorder (such as depression, bipolar disorder, anxiety) based upon a semi- structured diagnostic interview (must be a non-psychotic depressive disorder)
- Be at risk for developing mood disorders
- Healthy Control Group
Exclusion
- History of schizophrenia, schizoaffective disorders or chronic psychotic disorders based upon a semi-structured diagnostic interview.
- Unable to provide a stable home address and contact information.
- Has any condition for which, in the opinion of the investigator or designee, study participation would not be in their best interest (including but not limited to cognitive impairment, unstable general medical condition, intoxication, active psychosis) or that could prevent, limit, or confound the protocol-specified assessments.
- Requires immediate hospitalization for psychiatric disorder or suicidal risk as assessed by a licensed study clinician.
Key Trial Info
Start Date :
March 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2035
Estimated Enrollment :
6000 Patients enrolled
Trial Details
Trial ID
NCT06002204
Start Date
March 1 2024
End Date
February 1 2035
Last Update
August 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UT Southwestern Medical Center
Dallas, Texas, United States, 75390